Article Type
Original Research
Published
This subgroup analysis sought to more fully characterize the demographics, baseline characteristics, safety, and efficacy of
dalbavancin in the persons who inject drugs (PWID) and non-PWID population and as a single-dose therapy versus 2-dose therapy from a previously published global trial.
